## Pedro Castelo-Branco

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4049146/publications.pdf

Version: 2024-02-01

49 papers 5,034 citations

236925 25 h-index 214800 47 g-index

51 all docs

51 docs citations

51 times ranked

8475 citing authors

#	Article	IF	Citations
1	Post-transcriptional silencing of Bos taurus prion family genes and its impact on granulosa cell steroidogenesis. Biochemical and Biophysical Research Communications, 2022, 598, 95-99.	2.1	O
2	Correction for: Identification of colorectal cancer associated biomarkers: an integrated analysis of miRNA expression. Aging, 2022, 14, 2014-2015.	3.1	O
3	Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer Lacking Driver Mutations and Future Perspectives. Cancers, 2022, 14, 122.	3.7	16
4	CRISPR-based strategies in infectious disease diagnosis and therapy. Infection, 2021, 49, 377-385.	4.7	19
5	Marine Natural Products as a Promising Source of Therapeutic Compounds to Target Cancer Stem Cells. Current Medicinal Chemistry, 2021, 28, 4343-4355.	2.4	8
6	Current and potential biomarkers in gastric cancer: a critical review of the literature. Future Oncology, 2021, 17, 3383-3396.	2.4	16
7	Identification of colorectal cancer associated biomarkers: an integrated analysis of miRNA expression. Aging, 2021, 13, 21991-22029.	3.1	15
8	Dual role of allele-specific DNA hypermethylation within the TERT promoter in cancer. Journal of Clinical Investigation, 2021, 131, .	8.2	11
9	Screening for Colorectal Cancer Leading into a New Decade: The "Roaring â€~20s―for Epigenetic Biomarkers?. Current Oncology, 2021, 28, 4874-4893.	2.2	9
10	DNA Methylation of PI3K/AKT Pathway-Related Genes Predicts Outcome in Patients with Pancreatic Cancer: A Comprehensive Bioinformatics-Based Study. Cancers, 2021, 13, 6354.	3.7	3
11	Epigenetic Profiling in Severe Sepsis: A Pilot Study of DNA Methylation Profiles in Critical Illness*. Critical Care Medicine, 2020, 48, 142-150.	0.9	42
12	New Target Therapies in Advanced Non-Small Cell Lung Cancer: A Review of the Literature and Future Perspectives. Journal of Clinical Medicine, 2020, 9, 3543.	2.4	28
13	Epigenetics of Sepsis. Critical Care Medicine, 2020, 48, 745-756.	0.9	41
14	Comparative cost-effectiveness analysis of avelumab plus axitinib versus pembrolizumab plus axitinib, ipilimumab plus nivolumab, and sunitnib for advanced renal cell carcinoma in the U.K. Perspective Journal of Clinical Oncology, 2020, 38, 689-689.	1.6	2
15	Current and future aspects of TIM-3 as biomarker or as potential targeted in non-small cell lung cancer scope: is there a role in clinical practice?. Translational Lung Cancer Research, 2020, 9, 2311-2314.	2.8	6
16	Cellular Interactions in the Tumor Microenvironment: The Role of Secretome. Journal of Cancer, 2019, 10, 4574-4587.	2.5	91
17	Hot topics in epigenetic regulation of cancer self-renewal for pancreatic tumors: future trends. Future Oncology, 2019, 15, 683-685.	2.4	2
18	PALOMA-3 clinical trial: is there a significant benefit in overall survival for breast cancer? Is it worth it?. Future Oncology, 2019, 15, 1407-1410.	2.4	4

#	Article	IF	CITATIONS
19	Roadmap of DNA methylation in breast cancer identifies novel prognostic biomarkers. BMC Cancer, 2019, 19, 219.	2.6	90
20	Combined genetic and epigenetic alterations of the <i>TERT</i> promoter affect clinical and biological behavior of bladder cancer. International Journal of Cancer, 2019, 144, 1676-1684.	5.1	57
21	Lung cancer: a brief review of epidemiology and screening. Future Oncology, 2018, 14, 567-575.	2.4	24
22	DNA hypermethylation within TERT promoter upregulates TERT expression in cancer. Journal of Clinical Investigation, 2018, 129, 223-229.	8.2	130
23	What Will We Expect From Novel Therapies to Esophageal and Gastric Malignancies?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 249-261.	3.8	3
24	MetaLanc9 as a novel biomarker for non-small cell lung cancer: promising treatments via a PGK1-activated AKT/mTOR pathway. Journal of Thoracic Disease, 2018, 10, S2076-S2078.	1.4	11
25	Comparative outcome assessment of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small-cell lung cancer: a network meta-analysis. Oncotarget, 2018, 9, 11805-11815.	1.8	9
26	Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer. Journal of Biomedical Science, 2018, 25, 22.	7.0	172
27	Serum miRNA to predict post-chemotherapy viable disease in testicular non-seminomatous germ cell tumor patients Journal of Clinical Oncology, 2018, 36, 546-546.	1.6	0
28	The TERT hypermethylated oncologic region predicts recurrence and survival in pancreatic cancer. Future Oncology, 2017, 13, 2045-2051.	2.4	17
29	Cancer Stem Cells in Prostate Cancer: Implications for Targeted Therapy. Urologia Internationalis, 2017, 99, 125-136.	1.3	61
30	Epigenetic therapy in urologic cancers: an update on clinical trials. Oncotarget, 2017, 8, 12484-12500.	1.8	35
31	Epigenetic regulation of cancer self-renewal differs between endocrine tumors Journal of Clinical Oncology, 2017, 35, e15717-e15717.	1.6	0
32	Telomere dysfunction and chromothripsis. International Journal of Cancer, 2016, 138, 2905-2914.	5.1	42
33	A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarker. Immunotherapy, 2016, 8, 1011-1019.	2.0	34
34	Current advances in targeted therapies for metastatic gastric cancer: improving patient care. Future Oncology, 2016, 12, 839-854.	2.4	3
35	A cancer specific hypermethylation signature of the TERT promoter predicts biochemical relapse in prostate cancer: a retrospective cohort study. Oncotarget, 2016, 7, 57726-57736.	1.8	55
36	<i>BRAF</i> Mutation and <i>CDKN2A</i> Deletion Define a Clinically Distinct Subgroup of Childhood Secondary High-Grade Glioma. Journal of Clinical Oncology, 2015, 33, 1015-1022.	1.6	244

#	Article	IF	Citations
37	Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells. Acta Neuropathologica, 2014, 128, 863-877.	7.7	34
38	Alternative lengthening of telomeres is enriched in, and impacts survival of TP53 mutant pediatric malignant brain tumors. Acta Neuropathologica, 2014, 128, 853-862.	7.7	46
39	WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. Acta Neuropathologica Communications, 2014, 2, 174.	5.2	37
40	Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nature Genetics, 2014, 46, 451-456.	21.4	525
41	Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study. Lancet Oncology, The, 2013, 14, 534-542.	10.7	212
42	Subgroup-Specific Prognostic Implications of <i>TP53</i> Mutation in Medulloblastoma. Journal of Clinical Oncology, 2013, 31, 2927-2935.	1.6	381
43	Promises and challenges of exhausting pediatric neural cancer stem cells. Pediatric Research, 2012, 71, 523-528.	2.3	6
44	Monoallelic Expression Determines Oncogenic Progression and Outcome in Benign and Malignant Brain Tumors. Cancer Research, 2012, 72, 636-644.	0.9	56
45	Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature, 2012, 482, 226-231.	27.8	2,129
46	Neural Tumor-Initiating Cells Have Distinct Telomere Maintenance and Can be Safely Targeted for Telomerase Inhibition. Clinical Cancer Research, 2011, 17, 111-121.	7.0	53
47	Trichostatin A and Oncolytic HSV Combination Therapy Shows Enhanced Antitumoral and Antiangiogenic Effects. Molecular Therapy, 2008, 16, 1041-1047.	8.2	74
48	Homologous gene sequences mediate transcription-domain formation. Journal of Cell Science, 2006, 119, 3876-3887.	2.0	10
49	Polypyrimidine Tract Binding Protein Modulates Efficiency of Polyadenylation. Molecular and Cellular Biology, 2004, 24, 4174-4183.	2.3	155